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1. Introduction 
Recent studies indicated that oxidative stress has a causal role in the carcinogenesis of 
mainly two histological subtypes of ovarian cancer, namely, clear cell carcinoma and 
endometrioid adenocarcinoma. Because of recurrent hemorrhage in endometrial cysts, 
excess of reactive oxygen species are produced due to iron deposition, which results in 
direct genomic mutation of the epithelial cells and exaggeration of oxidative stress by 
stromal cells such as macrophages. In endometriosis-associated ovarian cancer, genomic 
mutations in specific genes such as ARID1A, p53, K-ras, PTEN, PI3CA and Met have been 
reported. Mechanism of carcinogenesis, especially focusing on the precise role of oxidative 
stress, remains to be clarified. Development of novel drugs and methods for therapy or 
prevention of endometriosis-associated ovarian cancer is necessary.  
2. Risk of cancer development in endometriosis 
Endometriosis is a common disease affecting 10 to 15% of women of reproductive age 
(Irving, 2011). An association between endometriosis and cancer was reported as early as 
the 1920s in English publications. Sampson (Sampson, 1925) proposed that endometrial 
carcinoma of the ovary develops from endometrial tissue, based on classic microscopic 
observation using several strict criteria (i.e., the coexistence of benign and malignant tissue 
with a shared histologic relationship in the same organ and evidence against invasion from 
other sites or sources). Further studies were interrupted by World War II; however, in the 
late 1940s and 1950s, several groups published case reports that met Sampson’s criteria 
(Scott, 1953; Postoloff & Rodenberg, 1955). Although none of the studies demonstrated any 
direct evidence, the consensus of the major researchers in the field at that time was that 
malignant transformation or transition occurred in ovarian endometriosis.  
In 1990, Heaps et al. analyzed 195 cases that mostly fulfilled Sampson’s criteria (Heaps, 
1990). They found that the primary endometriosis site was most frequently the ovary 
(78.7%), followed by various other sites such as the pelvis, rectovaginal septum, colon or 
rectum, or the vagina. The most frequent histologic subtype was endometrioid 
adenocarcinoma in either of the primary sites, ovarian (69%) or extragonadal (66%), 
followed by clear cell carcinoma and sarcoma in 13.5% and 11.6% of ovarian tumors, 
respectively, and sarcomas in 25% of extragonadal tumors. More recently, an elevated risk 
of ovarian cancer development in endometriosis has been shown by statistical analyses. A 
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direct prospective study of 20,686 Swedish patients hospitalized with endometriosis 
between 1969 and 1983 with a mean follow-up period of 11.4 years demonstrated a 
standardized incidence ratio (SIR) of 1.9 and a 95% confidence interval [CI] of 1.3 to 2.8 
(Brinton, 1997). Similar results were reported in a case-control study analyzing patients from 
the United States, in which the relative risk for ovarian cancer development in 
endometriosis patients was 1.7 (Ness, 2000). A nationwide case-control study of Australian 
patients with ovarian cancer revealed that endometriosis increased the risks of both 
endometrioid adenocarcinoma and clear cell carcinoma, with odds ratios of 3.0 and 2.2, 
respectively (Nagle, 2008). A recent retrospective study from Canada also showed a 
significant increase in the relative risk (rate ratio [RR], 1.6; 95% CI, 1.12 to 2.09) of ovarian 
cancer in patients with endometriosis (Aris, 2010). In line with these reports, a recent 
prospective study from Japan showed a significant and much greater elevation in the 
relative risk (SIR, 8.95; CI, 4.12 to 115.3) of cancer development in Japanese patients with 
endometrioma, or endometrial cyst of the ovary (Kobayashi, 2007). The reason for this 
discrepancy is unclear, but one possibility is that the endometriosis patients in the Japanese 
study included only those with clinically detectable ovarian endometrial cysts.  It is also 
important to note that Danazol (17-α-ethinltestosterone), a synthetic androgen that has been 
used to treat endometriosis, has been revealed to be an independent risk factor for the 
development of ovarian cancer. A negative correlation between oral contraceptive use and 
ovarian cancer, regardless of histologic type other than mucinous tumors, was recently 
shown by a collaboration of various groups worldwide (Cottreau, 2003). These factors may 
also influence the relative risk of ovarian cancer development.  
In addition to an epidemiologic approach, the retrospective pathological analysis of samples 
from ovarian cancer patients is also useful to confirm the presence of endometriosis 
associated with ovarian cancers of various histological types. A comprehensive review of 
2,807 ovarian cancer patients from 15 independent publications from western countries from 
the 1970s to 1990s, including 3 articles from Japan, revealed that endometriosis was 
incidentally found in 14.1% of ovarian cancer patients (39.2%, 21.2%, 3.3% and 3.0% of clear 
cell, endometrioid, serous and mucinous carcinoma patients, respectively), with a tendency 
toward a higher incidence of endometriosis in Japanese patients with clear cell carcinoma 
(Yoshikawa, 2000).  
3. Pathogenesis of endometriosis-associated ovarian cancer; the role of iron 
overload-induced oxidative stress 
Endometrial cysts, or so-called chocolate cysts, are well-known lesions in endometriosis that 
contain fluid with an excess of free iron because of recurring hemorrhage in the cyst. It is 
interesting to note that Sampson mentioned in his first report of endometriosis-associated 
cancer that old hemorrhages should be considered additional evidence that meets his 
criteria (Sampson, 1925). Hemosiderin, heme, or iron deposition in endometriotic lesions 
have been assumed to trigger oxidative damage and chronic inflammation (Van 
Langendonckt, 2002a; Van Langendonckt, 2002b; Van Langendonckt, 2004; Toyokuni, 2009). 
In particular, iron storage in macrophages is significantly increased in patients with 
endometriosis; and intracellular iron activates the nuclear factor-κB pathway and 
exaggerates chronic inflammation (Lousse, 2009; Lousse, 2008). As a result, prominent 
oxidative stress, or an excess of reactive oxygen species, is consistently produced. This 
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process is thought to have a causative role in endometriosis development and progression, 
leading to carcinogenesis (Murphy, 1998; Ness & Cottreau, 1999; Ngo, 2009). Alternatively, 
the high concentration of free iron in endometrial cysts may directly provide oxidative stress 
that induces genomic mutation in epithelial cells (Yamaguchi, 2008), and whether the direct 
pathway or the indirect pathway involving macrophages has a major role in carcinogenesis 
remains to be resolved. Iron overload in experimental animals enhances epithelial cell 
proliferation (Defrere, 2006) and causes malignant tumors with genomic abnormalities (Hu, 
2010), which suggests a similar mechanism leading to carcinogenesis in human 
endometriosis (Fig. 1).  However, further studies are awaited to elucidate the precise role of 
iron-deposition induced oxidative stress in carcinogenesis of endometriosis-associated 
cancer.  
 
Fig. 1. A proposed mechanism of carcinogenesis in endometriotic (chocolate) cysts 
4. Precancerous lesions in endometriosis 
Endometriosis itself is generally considered a benign disease; however, endometriosis 
shares certain features with cancer, including the ability of cells from different lineages 
(i.e., epithelial cells, stromal cells, and the vasculature) to proliferate in ectopic sites. Thus, 
earlier studies have focused on the clonal or malignant potential of endometriosis by 
analyzing the loss of heterozygosity (LOH) at several candidate tumor suppressor gene 
loci. Positive results, such as the detection of LOH at the p53, p16 or PTEN gene, were 
observed in the majority of the endometriosis samples ((Jiang, 1996; Jiang, 1998; Sato, 
2000), for review of other studies with similar results, see (Prowse, 2005)). Another 
approach, which assesses the clonality of endometriosis samples by analyzing 
methylation-related marker genes, also demonstrated the clonal nature of endometriosis 
(Jimbo, 1997). The findings, together with the LOH analysis, led to the conclusion that 
endometriosis was a neoplasm that may even have malignant potential. However, recent 
studies deny the malignant or neoplastic potential of endometriosis, demonstrating that 
most endometriosis tissues are not monoclonal (Mayr, 2003). Furthermore, neither LOH of 
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tumor suppressor genes, promoter methylation of oncogenes, nor oncogenic mutations of 
known tumor-related genes was frequently observed in the majority of the cases, further 
denying the neoplastic theory (Prowse, 2005; Vestergaard AL, 2011). In contrast with these 
results, a third approach (fluorescent in situ hybridization [FISH]) used to investigate 
chromosomal aberrations in endometriosis samples revealed a significantly elevated 
proportion of aneusomic (monosomic > trisomic) cells in endometriosis in multiple 
groups (Koerner, 2006) (Bischoff, 2002). However, both endometriosis tissue and normal 
endometrium also contain a certain proportion of aneusomic cells (Koerner, 2006), and 
telomerase expression, telomere elongation, higher expression of DNA replication 
markers and lower expression of DNA damage response markers are all observed in 
endometriosis tissue, but not in normal endometrium (Hapangama, 2008; Hapangama, 
2009). Thus, it may be reasonable to conclude that although endometriosis is generally 
considered non-neoplastic, the relative rates of abnormal cells are higher in endometriosis 
than in normal endometrium.  
In this case, then, which cells are premalignant? Is there a focal area representing the 
precancerous state of endometriosis that is morphologically distinguishable from other, 
presumably benign, areas? “Atypical endometriosis” is the term used to describe this state, 
which has been found in cases of extraovarian and ovarian cancer as atypical epithelium 
showing hyperchromatism and stratification continuous with the malignant tumor 
(Brooks&Wheeler, 1977; Lagrenade&Silverberg, 1988). Fukunaga et al. found atypical 
endometriosis in 61% of endometriosis-associated ovarian cancers, in contrast with 1.7% of 
benign endometriosis samples (Fukunaga, 1997). Immunohistochemical markers 
distinguishing atypical endometriosis from benign endometriosis have not been fully 
established, but staining patterns of Ki67, Bcl-2, and p53 have been reported as useful 
markers (Nezhat, 2002; Ogawa, 2000). Extraovarian endometriosis may also show atypical 
changes. Hyperplastic changes, including atypical hyperplasia and malignant changes, were 
observed in more than half of the adenomyosis cases associated with endometrioid 
adenocarcinoma arising from the endometrium (Jacques&Lawrence, 1990; Kucera, 2011), 
and histologically atypical hyperplasia has been reported in some cases of gastrointestinal 
endometriosis (Yantiss, 2000).  
5. Histological characteristics of endometriosis-associated malignancies 
Clear cell carcinoma (Fig. 2) and endometrioid adenocarcinoma are well-known histological 
subtypes in ovarian cancer associated with endometriosis (Fukunaga, 1997; Heaps, 1990; 
Modesitt, 2002; Ogawa, 2000; Yoshikawa, 2000). Endometrioid adenocarcinoma is the most 
frequently observed phenotype in western countries (Heaps, 1990; Modesitt, 2002); 
however, clear cell carcinoma predominates in the Japanese cases (Ogawa, 2000; Yoshikawa, 
2000). Veras et al. recently subdivided clear cell carcinoma into 3 groups (cystic, 
adenofibromatous, and indeterminate clear cell carcinoma) to further reveal the association 
between endometriosis and cystic clear cell carcinoma subtypes (Veras, 2009). Endometrioid 
adenocarcinomas arising in endometriotic lesions are often Grade 1 at presentation 
(Horiuchi, 2003), mostly showing typical morphology with various degrees of squamous 
differentiation (Heaps, 1990; Staats, 2007), similar to endometrioid adenocarcinoma without 
endometriosis. Sarcomas are the second and third most frequent endometriosis-associated 
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extraovarian and ovarian tumors, respectively. Adenosarcoma and endometrial stromal 
sarcoma are the major histological types of sarcomas (Baiocchi, 1990; Heaps, 1990; Slavin, 
2000). At least partially, differences in the incidences of tumor types (carcinoma versus 
sarcoma) depend on the tumor site, and further studies are needed to elucidate this 
mechanism. Other rare malignant tumors, such as squamous cell carcinoma, malignant 
mesodermal mixed tumor, and yolk sac tumor, are also reported to develop from 
endometriosis (Irving, 2011). Although its incidence is very low compared with 
endometrioid adenocarcinoma or clear cell carcinoma, serous adenocarcinoma has also been 
associated with endometriosis (Fukunaga, 1997; Modesitt, 2002; Yoshikawa, 2000). Much 
more rarely, mucinous carcinomas with unusual morphology resembling Mullerian 
mucinous borderline tumors have also been reported in association with endometriosis 
(Lee&Nucci, 2003).  
 
Fig. 2. A. Clear cell carcinoma (left) arising in a endometriotic cyst. B. Hemosiderin 
deposition (arrows) is observed in the stroma of clear cell carcinoma.  
6. Genetic abnormalities and phenotypes of endometriosis-associated 
ovarian cancer 
Genetic mutations specifically associated with ovarian cancer subtypes have been reported 
(reviewed by (Kurman&Shih, 2011)). Focusing on endometrioid adenocarcinomas, genetic 
mutations of K-ras, p53, PTEN, beta-catenin, and ATR have been reported ( Mizuuchi, 1992; 
Milner, 1993; Palacios&Gamallo, 1998; Tashiro, 1997; Zighelboim, 2009). Mouse models of 
endometrioid adenocarcinoma have been reported, either with oncogenic K-ras and 
conditional PTEN deletion (Dinulescu, 2005) or dysfunction of both the Wnt/beta-catenin 
and PI3CA/PTEN pathways (Wu, 2007). However, specific genetic alterations of clear cell 
carcinoma were mostly unknown. Recently, a frequently activated mutation of the PI3CA 
gene was observed in clear cell carcinoma samples (Kuo, 2009). Most recently, several 
studies based on novel sequencing technology have elucidated that a significant proportion 
of clear cell carcinomas harbor a mutation of the ARID1A gene, which encodes the 
chromatin-remodeling complex protein BAF250A (Jones, 2010; Wiegand, 2010). ARID1A 
mutation and the consequent loss of BAF250A expression were found not only in clear cell 
carcinoma samples, but also in endometrioid adenocarcinomas, especially high-grade types 
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(Wiegand 2010; Wiegand, 2011). Whether ARID1A mutation is an early or late event in 
endometriosis-associated ovarian cancers related to atypical endometriosis remains to be 
elucidated. Alterations of other genes, such as p53, p16, and PTEN, have been detected in a 
low percentage of endometriotic lesions (Martini, 2002; Nezhat, 2008). hMLH, a DNA 
mismatch repair gene, is another candidate for the malignant transformation of 
endometriosis (Nyiraneza, 2010 ; Ren F, 2011). hMLH is the causal gene of Lynch syndrome, 
in which the risk of developing endometrial and ovarian cancers is significantly increased 
(Schmeler&Lu, 2008). K-ras may also be important because mutated K-ras promotes 
endometriosis in a mouse model, suggesting that K-ras mutation may be an early event in 
the carcinogenesis of endometriosis-associated cancers (Cheng, 2011). Finally, a single-
nucleotide polymorphism in the intron of ANRIL, a non-coding RNA that regulates p16 
expression, has been recently reported to have a strong association with endometriosis 
(Uno, 2010). The molecular steps from endometriosis development to carcinogenesis remain 
to be further clarified.    
Recent studies have proposed classifying ovarian cancers into two categories: Type I 
tumors, which rarely harbor the p53 mutation and have an indolent clinical course, and 
Type II tumors, which feature the p53 mutation and are aggressive (Kurman&Shih, 2010). 
Within endometriosis-associated ovarian cancers, low-grade endometrioid 
adenocarcinoma and clear cell carcinomas are considered Type I, while high-grade 
endometrioid adenocarcinoma is included in the Type II category. However, p53 
mutations are detected in both low- and high-grade endometriosis-associated ovarian 
endometrioid adenocarcinomas (Okuda, 2003), and PI3CA, PPP2R1A, and K-ras 
mutations are commonly detected in both endometrioid adenocarcinoma and clear cell 
carcinoma (Campbell, 2004; Jones, 2010 ; Kuo, 2009; McConechy, 2011 ; Mizuuchi, 1992). 
Recent evidence indicates that ovarian cancers arise from different cell lineages, such as 
preexisting cystadenomas, ectopic endometrium in endometriotic lesions, and epithelial 
cells of the Fallopian tubes (Bell, 2005; Kurman&Shih, 2011). Thus, it may be an 
oversimplification to divide all ovarian cancers into two groups. It may more accurate to 
categorize endometriosis-associated cancers into the same group, regardless of the 
histological subtype or tumor grade.   
Numerous studies of expression microarray analyses have been published. Cytokines and 
chemokines, such as interleukin-1 and its downstream factor cyclooxygenase (COX)-2, 
interleukin-8, TNF-α and its downstream VEGF, TGF- α, and interleukin-6 have been 
reported to be involved in endometriosis and endometriosis-associated carcinoma 
(reviewed by (Nezhat, 2008)). An interesting study by Banz et al. revealed that SICA2, 
CCL14, and TDGF1 were specifically upregulated in both endometriosis samples and 
endometriosis-associated endometrioid adenocarcinomas, in contrast with serous 
adenocarcinomas or normal ovarian tissues (Banz, 2010). Another microarray study 
focusing on endometriosis-associated clear cell carcinoma showed upregulation of 
hepatocyte nuclear factor (HNF)-1β, versican, and other markers related to oxidative 
stress (Yamaguchi, 2010).  HNF-1β is a transcription factor, involved in the regulation of 
glucose homeostasis and glycogen accumulation, normally expressed in the liver and 
other organs, which is assumed to have some role in the pathogenesis of clear cell 
carcinoma of the ovary (Kobayashi, 2009). Recently, a novel attempt to classify 
www.intechopen.com
 
Endometriosis-Associated Ovarian Cancer: The Role of Oxidative Stress 317 
histological subtypes using a small number of biomarkers has been applied to ovarian 
cancers. A tissue microarray-based analysis selected 21 markers, including CA125, 
estrogen receptor (ER), insulin-like growth factor 2 (IGF2), Ki-67, p21, p53, progesterone 
receptor (PGR), and Wilms tumor 1 (WT1), to distinguish histological subtypes; however, 
only three of the 21 markers could predict outcomes in only high-grade serous carcinoma 
patients (Koebel, 2008). More recently, however, Kalloger et al. succeeded in 
reproductively diagnosing five major subtypes of ovarian cancers (high-grade serous, 
clear cell, endometrioid, mucinous, and low-grade serous) using only nine markers: p16, 
DKK1 (a Wnt antagonist), HNF-1β, MDM2, PGR, trefoil factor 3 (TFF3), p53, vimentin, 
and WT1 (Kalloger, 2011). Immunohistochemical analysis of 155 cases by De Lair et al 
demonstrated that 89% of clear cell carcinoma had HNF-1β positive, ER, PGR, and WT1 
negative phenotype (DeLair, 2011).  
7. Prognosis of endometriosis-associated ovarian cancer 
Clear cell adenocarcinoma is known to be associated with chemoresistancy and a poor 
prognosis (Itamochi, 2008). However, most reports analyzing the prognosis of 
endometriosis-associated ovarian carcinomas (including mostly endometrioid 
adenocarcinoma and few clear cell carcinoma samples) have shown that endometriosis-
associated ovarian carcinomas presented at younger ages, in lower grades and stages, and 
had significantly better overall survival compared with age-matched controls without 
endometriosis (Erzen, 2001; Kumar, 2011; Melin, 2011 ; Orezzoli, 2008). However, recent 
studies from various countries indicate that clear cell carcinomas consist of heterogenous 
tumors with gene alterations, such as HER2 or Met gene amplification (Tan, 2011 ; 
Yamamoto, 2011; Yamashita, 2011). Therefore, clear cell carcinomas as a subtype are 
considered to have a worse prognosis than endometrioid adenocarcinomas, especially in 
Asian cases (Lee, 2011). Recently, the first international symposium of ovarian clear cell 
carcinoma concluded that although patients with low-stage clear cell carcinoma had a better 
prognosis than matched controls with high-grade serous carcinoma, high-stage clear cell 
carcinoma cases had the worst prognosis (Anglesio, 2010). Thus, alternative therapy, such as 
molecular targeted therapy, should be applied to these aggressive tumors, and a further 
understanding of the basic biology of the endometriosis-cancer progression, especially the 
role of oxidative stress, is necessary to prevent carcinogenesis in endometriosis patients 
(Aris, 2010).   
8. Conclusion 
We have reviewed the literature on endometriosis-associated ovarian cancer. Further 
studies are awaited to clarify the exact role of oxidative stress in carcinogenesis. 
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